EA3 study: Pulmonary diseases (IPF, asthma and COPD) study and data in Sandbox

If you wish to use EA3 data, please familiarize yourself with these instructions.

Sandbox directory

Latest version

/finngen/library-red/EA3_PULMO_1.0

Study description

Expansion Area 3 (EA3) studies aim to acquire additional clinical data centered around specific diseases through biobanks.

Aim: The pulmonary deep phenotyping study aimed to provide more specific differentiation of interstitial lung diseases (idiopatic pulmonary fibrosis (IPF) in particular), asthma, and chronic obstructive pulmonary disease (COPD) and other sub-phenotypes and their progression which enables more specific evaluation of genetic impact in these diseases. Pulmonary diseases were selected as an EA3 study trait due to lack of specific differentiation of these diseases, and the available clinical data could improve registry-based diagnoses significantly.

Methods: Data was captured altogether from six biobanks: Auria, Helsinki, Tampere, Borealis, Central Finland and Eastern Finland biobanks. Laboratory database searches were done for relevant biomarkers: immunoglobulin E as marker for atopic constitution, all available blood counts for leukocytes, lymphocytes, eosinophils, and neutrophils to subphenotype asthma, and for CRP. Pulmonary data also contains hospital administrated drug data (Mepolizumab, Omalizumab, Bennralizumab, Reslizumab, and Dupilumab). Furthermore, at Auria and Central Finland biobanks, spirometry data were also retrieved. Physiological measurement searches were done for structural format BMI, heigh, weight, smoking and smoking pack years. These were retrieved at Auria Biobank, Central Finland Biobank, Helsinki Biobank and Tampere Biobank.

Data: The pulmonary diseases data has been placed in the Sandbox and is available for analysis. Pulmonary diseases samples are from DF11 and the data has been collected from 6/6 hospital biobanks. Data collection time 1.1.2000-23.11.2022.

Summary of the data (Oct 2023):